Mounjaro 7mg: your third step on the treatment ladder

Step 1: how you arrive at 7mg

Treatment with Mounjaro begins at 2.5mg, a tolerability dose whose job is to let your body adjust rather than to produce maximum weight-loss effect. After four weeks, assuming the 2.5mg pen has been well tolerated, the prescriber typically moves you to 5mg. A further four weeks, another clinical review, and 7mg follows, if your prescriber is satisfied with both your response and how you have been managing any side effects.

That step-by-step design is deliberate. Gastrointestinal symptoms such as nausea, an unsettled stomach, or loose stools are most likely to surface when the dose changes, so slowing the climb gives each new strength time to settle. By the time most people reach 7mg they have already worked out when to eat, how much is comfortable, and which habits help them get the most from treatment. You can read more about the full licensed schedule on the Mounjaro dose overview page.

One thing a question our prescribers hear most weeks: "Can I stay on 7mg rather than going higher?" The answer is yes, in principle, the goal is the lowest dose that achieves the clinical outcomes your prescriber is aiming for. Not everyone needs 15mg. Some people stabilise well at 7mg or 7.5mg, and you can find more detail about that strength on the Mounjaro 7.5mg page, and the prescriber will assess your progress at each review rather than automatically pushing upward.

Step 2: what changes (and what doesn't) at this strength

The underlying mechanism does not change as the dose increases, tirzepatide is still activating both the GIP and GLP-1 receptors, slowing gastric emptying and signalling fullness earlier in a meal. What changes is the intensity of that effect. At 7mg, most people find appetite suppression is noticeably stronger than at 5mg, and early satiety during meals more consistent.

The 5mg step is often described, looking back, as the dose where things started to feel real; 7mg is where many people first notice their eating habits shifting in a sustained way rather than day-to-day. That said, individual responses vary considerably, and no prescriber or pharmacist can predict exactly how any given strength will feel for you.

The NHS patient information for tirzepatide (published at nhs.uk/medicines/tirzepatide) covers the common side effects you may still notice at 7mg: nausea, loose stools, constipation, indigestion, burping, fatigue and headache. These tend to follow the same pattern as the earlier steps: most noticeable in the first week or two after a dose change, then settling. If they don't settle, or if you experience severe persistent stomach pain, contact a healthcare professional promptly.

Step 3: the clinical review before each 7mg repeat

At nume, every repeat order (including your second or third pen at 7mg) goes through a fresh clinical review before it is dispensed. A prescriber looks at your progress: weight, any side effects you have reported, and whether continuing at this strength or moving to the next step is appropriate. This is the framework our clinical team operates to, and it reflects the standard the NICE appraisal of tirzepatide (TA1026) expects of weight-management treatment, ongoing clinical oversight rather than a one-time sign-off.

If you are transferring from another provider and already established on 7mg, your prescriber will ask for evidence of your current treatment and dose history before continuing. That step is not bureaucratic caution for its own sake, it is how a responsible prescriber confirms the right dose is being maintained in the right clinical context.

For a sense of what comes next if 7mg goes well, the 7.5mg page covers the following step, and the weight-loss treatment overview sets the full picture. If you are weighing up the cost of ongoing private treatment, there is useful context on the Mounjaro pricing page covering the September 2025 list-price changes.

Step 4: what this dose cannot tell you on its own

The 7mg pen delivers a specific weekly dose, but the number alone does not determine your outcome. Clinical trials like SURMOUNT-1 show that sustained weight reduction with tirzepatide correlates with dose, lifestyle changes alongside it, and duration of treatment, not any single pen's strength. The NICE guidance notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed.

That framing matters: 7mg is not a destination, it is a checkpoint. Your prescriber uses it to build a picture of how your body responds to tirzepatide, and that picture shapes every decision from here, whether to step up, hold, or in rare cases step back down temporarily, including to 4mg Mounjaro, which our dedicated page explains in full. If you have questions ahead of starting, the frequently asked questions page covers common concerns, and you are always welcome to get in touch with the team directly. When you are ready to take the next step, start your free consultation and our prescribers will review whether Mounjaro is clinically suitable for you.